Takeda’s US subsidiary launched its proton pump inhibitor dexlansoprazole last February under the name Kapidex. No one thought they’d have to find a new name a year later.
But shortly after the launch, the company began getting reports of dispensing errors. Some were due to prescription misreading, others to simple, honest mistakes. The two drugs causing [...]
Posted in Corporate Responsibility, FDA, Marketing, News, Safety, Strategy | Also tagged Casodex, chronic pain, dexlansoprazole, dispensing error, FDA, Kadian, Kapidex, Prostate cancer, proton pump inhibitor, Takeda
PharmExec Blog
Follow Us
RSS
Bookstore
Takeda Changes Dexlansoprazole Brand Name From Kapidex to Dexilant